ALNY•benzinga•
Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case
Summary
The Federal Circuit upheld a ruling that Moderna's COVID-19 vaccine does not infringe Alnylam's mRNA patents related to the SM-102 lipid used in Spikevax.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 5, 2025 by benzinga